By targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) on T cells, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) on tumor cells, this approach disrupts immunosuppressive signaling pathways and restores T-cell-mediated antitumor activity [4]. Here, PDCD1 is linked to neoplasm.